Perth, Sept 28, 2006 (ABN Newswire) - Clinical Cell Culture Ltd (ASX: CCE) today announced that it had entered into a supply agreement with CSL Limited (ASX: CSL) for the supply of Trypsin, a key component of the Company's ReCell(R) tissue harvesting device.

ReCell (R) is a unique medical device that assists plastic, cosmetic, dermatology and burn surgeons in repairing a wide range of skin defects. ReCell (R) is intended for use in patients with injuries of up to 2% of the body surface or 320cmSq.

Under the terms of the agreement, C3 has committed to a minimum quantity of Trypsin from CSL over a 2 year period, resulting in a financial commitment of $1 million.

CEO Bob Atwill said he was delighted that the supply of Trypsin had been secured with CSL, Australia's leading biopharmaceutical company. "This agreement locks in the supply of enhanced formulations of Trypsin and the minimum purchase quantity reflects the anticipated increase in ReCell(R) sales in the next 2 years."

"We have worked with CSL for a number of years and we look forward to developing our relationship in the supply of this key component," said Mr Atwill.

President Asia Pacific CSL Bioplasma Tom Giarla said this agreement will continue our close working partnership and enable us to jointly develop the Trypsin product and technology platform.

>>> CLINICAL CELL CULTURE LIMITED
>>> CSL LIMITED